Vm-26 (Teniposide)-induced hypersensitivity and degranulation of basophils in children

Journal of Pediatric Hematology/Oncology

Volumn 10, Issue 4, 1988, Pages 308-312

  Nolte, Hendrik ^a,b   Carstensen, Henrik ^a   Hertz, Henrik ^a  

^a Mental Health Center Glostrup   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cremaphor; Histamine liberation; Hyper; Sensitivity; Teniposide; VM 26; Vumon

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; TENIPOSIDE; VINCRISTINE;

CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; HISTAMINE RELEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROBLASTOMA; SYMPTOMATOLOGY;

ADOLESCENT; ALLERGENS; BASOPHILS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; FEMALE; HISTAMINE RELEASE; HUMAN; INFANT; MALE; NEUROBLASTOMA; PODOPHYLLOTOXIN; POLYETHYLENE GLYCOLS; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; TENIPOSIDE;

EID: 0023770014     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/00043426-198824000-00007     Document Type: Article

References (18)

1. Macbeth FR. VM-26: Phase I and II studies. Cancer Che mother Pharmacol 1982;7:87-91.
2. O’Dwyer PJ, Alonso MT, Leyland-Jones B, et al. Tenipo- side: A review of 12 years of experience. Cancer Treat Rep 1984;68:145-66.
3. Rivera G, Dahl GV, Murphy SB, et al. VM-26 therapy in children with drug refractory lymphocytic leukemia. Cancer Chemother Pharmacol 1982;7:169-72.
4. Creaven PJ. The clinical pharmacology of VM-26 and VP16- 213. A brief overview. Cancer Chemother Pharmacol 1982;7:133-40.
5. Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987;12:223-52.
6. Shimizu H, Frankel LS, Culbert SJ. Severe hypertensive, reactions to teniposide (VM-26) in infants with congenital leukemia. Am J Pediatr Hematol Oncol 1987;9:239-41.
7. O’Dweyer PJ, King SA, Fortner CL, et al. Hypersensitivity reactions to teniposide (VM-26): An analysis. J Clin Oncol 1986;4:1262-9.
8. Hayes FA, Abromowitch M, Green AA. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies. Cancer Treat Rep 1985;69:439-41.
9. Weiss RB. Hypersensitivity reactions to cancer chemotherapy. Semin Oncol 1982;9:5-13.
10. Carstensen H, Nolte H, Hertz H, et al. Hypersensitivity reactions to teniposide in children. J Clin Oncol 1987;5: 1491-2.
11. Nolte H, Schiptz PO, Skov PS. A new glass microfibre- based histamine analysis for allergy testing in children. Results compared with conventional leukocyte histamine release assay, skin prick test, bronchial provocation test and RAST. Allergy 1987;24:366-73.
12. Skov PS, Norn S, Weeke B. A new method for detecting histamine release. Agents Actions 1984;14:414-6.
13. Skov PS, Mosbech H, Norn S, et al. Sensitive glass microfi-bre-based histamine analysis for allergy testing in washed blood cells. Allergy 1985;40:213-8.
14. Skov PS, Jensen C, Nolte H, et al. Regulatory role of cell- bound IgE on histamine release. In: Schou JS, Geisler A, Norn S, eds. Drug receptors and dynamic processes in cells. Copenhagen: Munksgaard, 1986:245-54.
15. Skov PS, Permin H, Mailing HJ. Quantitative and qualitative estimations of IgE bound to basophil leukocytes from hay fever patients. Scand J Immunol 1977;6:1021-9.
16. Lorenz W, Schmal H, Schult H, et al. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: Analysis of various components in cremaphor El and development of a compound with reduced toxicity. Agents Actions 1982;12:65-80.
17. Lorenz W. Histamine release in man. Agents Actions 1975;5:402.
18. Ebbesen F, Skov PS, Jensen C, et al. Basophil histamine release in cord blood. Allergy 1986;41:562-7.